Spread the word: February 28 is the 10th International Rare Disease Day
FREIBURG, Germany, February 21, 2017
As a developer of innovative drugs for the treatment of rare diseases, Greenovation is committed to support the tenth international Rare Disease Day on 28 February 2017. Held on the last day of February every year, Rare Disease Day brings together patient organizations. The Rare Disease Day aims to improve the diagnosis and treatment of affected patients worldwide.
A disease or disorder is defined as rare in Europe when it affects fewer than one in 2000. In the US for example a disease or disorder is defined as rare when it affects fewer than 200,000 Americans. Most rare diseases are congenital genetic disorders, which may have serious, life-threatening symptoms that begin in childhood. Around half of rare diseases affect children.
However, there is a wide variety of rare diseases. About 6,000 to 7,000 different rare diseases have been identified. While there may only be a handful of patients affected by an individual disease, overall, rare diseases affect around 300 million people worldwide.
Although in some rare diseases effective therapies are available, correct diagnosis is still a challenge. This means many patients receive appropriate medical care too late, or even not at all. Awareness and Research and development will ensure that affected people get access to early diagnosis and appropriate and effective treatment.
“We at Greenovation want to help patients with rare diseases lead a better life.”, says Dr. Thomas Frischmuth, CEO at Greenovation. “That is why we are developing innovative biopharmaceutical replacement therapies for rare diseases such as Fabry's disease and atypical hemolytic-uraemic syndrome.”
About Greenovation Biotech GmbH
Greenovation develops next-generation therapeutics for the treatment of rare diseases.
Greenovation is a privately owned biopharmaceutical company based in Heilbronn, Germany. It was founded in 1999 by Prof. Dr. Ralf Reski and Prof. Dr. Gunter Neuhaus. Today, Greenovation Biotech GmbH is majority-owned by Zukunftsfonds Heilbronn and L-EigenkapitalAgentur (Karlsruhe).